Bupropion is the Single Medication That Addresses All Four Conditions
Bupropion (extended-release formulation) is the only medication with evidence supporting efficacy across depression, anxiety, ADHD, and hypertension management in adults. This recommendation is based on its established role as an antidepressant 1, demonstrated efficacy for adult ADHD 2, 3, anxiolytic properties through its use in depression with anxiety features, and notably, its lack of hypertensive effects (unlike stimulants which are contraindicated in uncontrolled hypertension).
Rationale for Bupropion
Depression Treatment
Bupropion is a second-generation antidepressant with established efficacy for major depressive disorder 1. The 2023 ACP guideline indicates that antidepressants show similar benefits to other first-step MDD treatments, though clinicians should consider adverse event profiles when selecting agents.
ADHD Management
For adult ADHD, bupropion demonstrates moderate efficacy with low-quality evidence showing decreased ADHD symptom severity (SMD -0.50) and increased clinical improvement rates (RR 1.50) 2. While stimulants remain first-line per clinical guidelines 4, bupropion serves as the primary alternative for adults unable to take stimulants or with concurrent depression/anxiety 4. The meta-analysis of bupropion for adult ADHD showed beneficial effects with odds ratio 2.42 for clinical improvement 3.
Anxiety Component
Bupropion addresses anxiety symptoms particularly when they co-occur with depression. Given that 74 million low-income US adults show associations between anxiety/depression and hypertension 5, and that comorbid depression-ADHD presentations involve significant emotional dysregulation 6, bupropion's dual antidepressant-ADHD effects provide coverage for anxiety symptoms within these complex presentations.
Hypertension Compatibility
Critically, bupropion does not elevate blood pressure, making it safe in hypertensive patients - a key advantage over stimulant medications which can increase BP and heart rate. The 2025 AHA/ACC hypertension guideline recommends initiating combination antihypertensive therapy for stage 2 hypertension (BP ≥140/90) 7, but does not contraindicate bupropion use. Standard first-line antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) should be prescribed separately according to BP staging 7.
Dosing Algorithm
- Start bupropion extended-release 150 mg daily for one week
- Increase to 300 mg daily (target therapeutic dose for both depression and ADHD)
- Maximum dose 450 mg daily if needed for ADHD symptoms 2
- Treatment duration: minimum 6-10 weeks to assess response 2
Critical Caveats
Seizure risk: Bupropion lowers seizure threshold - avoid in patients with seizure disorders, eating disorders, or abrupt alcohol/benzodiazepine withdrawal
Monitoring requirements: Despite similar tolerability to placebo in ADHD trials (RR 1.20 for withdrawal due to adverse effects) 2, monitor for:
- Psychiatric symptoms: mood changes, anxiety worsening, psychosis 8
- Physical symptoms: appetite suppression, insomnia, tremor
- Cardiac symptoms: though BP typically unaffected, monitor heart rate
Limitations of evidence: The ADHD evidence is low-quality with small sample sizes and short study durations (6-10 weeks) 2. Effect size is smaller than stimulants, but bupropion remains the best single-agent option when stimulants are contraindicated.
Concurrent Hypertension Management
Separately initiate antihypertensive therapy based on BP staging 7:
- Stage 2 hypertension (≥140/90): Start two-drug combination, preferably single-pill combination (ACE inhibitor or ARB + thiazide or calcium channel blocker)
- Stage 1 hypertension (130-139/80-89): Single first-line agent with titration as needed
The hypertension treatment is independent of bupropion therapy and should follow standard BP management algorithms 7.